MAIA Biotechnology, Inc. Research and Development Expense
MAIA Biotechnology, Inc. (MAIA) reported Research and Development Expense of $222.76 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- MAIA Biotechnology, Inc. research and development expense for the quarter ending 2026-06-30 was $179.11K.
- MAIA Biotechnology, Inc. research and development expense for the quarter ending 2026-03-31 was $43.65K, a 98.63% decline year-over-year.
- MAIA Biotechnology, Inc. research and development expense for the quarter ending 2025-06-30 was -$3.17M, a 254.31% decline year-over-year.
- MAIA Biotechnology, Inc. research and development expense for the quarter ending 2025-03-31 was $3.20M, a 37.78% increase year-over-year.
- MAIA Biotechnology, Inc. research and development expense for fiscal 2025 was $453.75K, a 95.47% decline from fiscal 2024.
- MAIA Biotechnology, Inc. research and development expense for fiscal 2024 was $10.01M, a 9.93% decline from fiscal 2023.
- MAIA Biotechnology, Inc. research and development expense for fiscal 2023 was $11.11M, a 24.39% increase from fiscal 2022.
- MAIA Biotechnology, Inc. research and development expense for fiscal 2022 was $8.93M, a 155.47% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $179.11K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $222.76K 10-Q · filed 2026-08-10 | ||
| 2026-03-31 | $43.65K 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $453.75K 10-K · filed 2026-03-23 | |||
| 2025-06-30 | -$3.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $30.75K 10-Q · filed 2026-08-10 | $3.00M derived: sum of 3 quarters · filed 2026-08-10 | $5.67M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $3.20M 10-Q · filed 2025-05-09 | $6.17M derived: sum of 2 quarters · filed 2025-05-09 | $8.83M derived: sum of 3 quarters · filed 2025-05-09 | $10.89M derived: sum of 4 quarters · filed 2025-05-09 |
| 2024-12-31 | $2.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $5.64M derived: sum of 2 quarters · filed 2025-03-21 | $7.69M derived: sum of 3 quarters · filed 2025-03-21 | $10.01M 10-K · filed 2025-03-21 |
| 2024-09-30 | $2.67M 10-Q · filed 2024-11-12 | $4.72M derived: sum of 2 quarters · filed 2024-11-12 | $7.04M 10-Q · filed 2024-11-12 | $10.76M derived: sum of 4 quarters · filed 2025-05-09 |
| 2024-06-30 | $2.05M 10-Q · filed 2024-08-09 | $4.37M 10-Q · filed 2024-08-09 | $8.09M derived: sum of 3 quarters · filed 2025-05-09 | $10.69M derived: sum of 4 quarters · filed 2025-05-09 |
| 2024-03-31 | $2.32M 10-Q · filed 2025-05-09 | $6.04M derived: sum of 2 quarters · filed 2025-05-09 | $8.64M derived: sum of 3 quarters · filed 2025-05-09 | $11.24M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $3.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $6.32M derived: sum of 2 quarters · filed 2025-03-21 | $8.92M derived: sum of 3 quarters · filed 2025-03-21 | $11.11M 10-K · filed 2025-03-21 |
| 2023-09-30 | $2.60M 10-Q · filed 2024-11-12 | $5.20M derived: sum of 2 quarters · filed 2024-11-12 | $7.39M 10-Q · filed 2024-11-12 | $9.79M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $2.60M 10-Q · filed 2024-08-09 | $4.80M 10-Q · filed 2024-08-09 | $7.19M derived: sum of 3 quarters · filed 2024-08-09 | $9.53M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $2.20M 10-Q · filed 2024-05-14 | $4.59M derived: sum of 2 quarters · filed 2024-05-14 | $6.93M derived: sum of 3 quarters · filed 2024-05-14 | $9.05M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $2.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $4.74M derived: sum of 2 quarters · filed 2024-03-21 | $6.86M derived: sum of 3 quarters · filed 2024-03-21 | $8.93M 10-K · filed 2024-03-21 |
| 2022-09-30 | $2.34M 10-Q · filed 2023-11-07 | $4.46M derived: sum of 2 quarters · filed 2023-11-07 | $6.54M 10-Q · filed 2023-11-07 | $8.05M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $2.12M 10-Q · filed 2023-08-08 | $4.20M 10-Q · filed 2023-08-08 | $5.71M derived: sum of 3 quarters · filed 2023-08-08 | $6.79M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $2.08M 10-Q · filed 2023-05-08 | $3.59M derived: sum of 2 quarters · filed 2023-05-08 | $4.67M derived: sum of 3 quarters · filed 2023-05-08 | $5.31M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $1.51M derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-03-24 | $2.59M derived: sum of 2 quarters · filed 2023-03-24 | $3.23M derived: sum of 3 quarters · filed 2023-03-24 | $3.50M 10-K · filed 2023-03-24 |
| 2021-09-30 | $1.08M 10-Q/A · filed 2023-02-06 | $1.73M derived: sum of 2 quarters · filed 2023-02-06 | $1.99M 10-Q/A · filed 2023-02-06 | |
| 2021-06-30 | $643.99K 10-Q · filed 2022-08-22 | $906.75K 10-Q · filed 2022-08-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |